🇺🇸 FDA
Patent

US 11485758

Bi-terminal pegylated integrin-binding peptides and methods of use thereof

granted A61KA61K31/337A61K38/00

Quick answer

US patent 11485758 (Bi-terminal pegylated integrin-binding peptides and methods of use thereof) held by The Regents of the University of California expires Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Nov 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K31/337, A61K38/00, A61K47/60, A61K47/64